Provided is the combination of ruxolitinib (A) ((R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-lyl)-3-cyclopentylpropanenitrile) and panobinostat (B) (N-hydroxy-3-[4-[[[2-(2 -methyl-1H-indol-3-yl)-ethyl]amino]methyl]phenyl]-2E-2-propenamide. The combination is useful in the treatment of cancer, particularly, myeloproliferative neoplasms. Examples of myeloproliferative neoplasms include chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), primary or idiopathic myelofibrosis (PMF), chronic neutrophilic leukemia, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, hypereosinophilic syndrome, systemic mastocytosis, and atypical chronic myelogenous leukemia.